Developing COVID-19 Vaccines in Record Time, Part 4: Update on Vaccines

November 8, 2021

COVID-19 Vaccine Update Part 4 – Updates from vaccine developers regarding COVID-19 vaccines for children and adults.

This webinar, supported by the National Adult and Influenza Immunization Summit (NAIIS), featured updates from COVID-19 vaccine developers regarding COVID-19 vaccines for adults and children. This is the 4th in a series of webinars featuring vaccine manufacturers presenting their latest updates on COVID-19 vaccine research for specific populations, development, and rollout. We featured presentations from companies with currently available COVID-19 vaccines, and/or vaccine candidates in later clinical trial phases (Phase 2/3) as well vaccines in earlier phases of clinical development. We asked all companies to present updates on either: (1) published or other data plus timing of next phase of trials; (2) published Phase 2 data as well as a description and updates on the progress of Phase 3 trials; or (3) current vaccines and their roll out; availability of doses over the next few months; and/or other developments with regard to dosing or formulation that would be of interest to NAIIS partners.

After the presentations, there was a moderated discussion of scientific and implementation topics: understanding of the variants/mutations of SARS-CoV2 and the vaccines; thoughts about duration of immunity, impact of vaccination on transmission, and industry thoughts on potential changes in formulations as the SARS-CoV-2 viruses continue to evolve. Questions for the attendees were also taken.

This meeting was moderated by Phyllis Arthur, Vice President, Infectious Diseases & Emerging Science Policy, at BIO. We at the Summit are delighted and grateful for this opportunity to collaborate with BIO on this important discussion.

PANELISTS

• Pfizer 
  Phil Dormitzer MD, PhD
  Vice President and Chief Strategy Officer, Viral Vaccines
  (presentation not posted per presenter’s request)

• Moderna (slides)
  James Mansi, PhD 
  Vice President of Medical Affairs-Americas
  Video: Moderna: Update to the mRNA-1273 COVID-19 Vaccine Program
  

• Johnson & Johnson (slides)
  Chime Nnadi , MD, PhD
  Senior Director, US Vaccine Medical Affairs, Janssen Infectious Diseases & Vaccines
  Video: J&J: COVID-19 Vaccine Update Webinar Series

• Novavax (slides)
  Seth Toback, MD, FAAP
  Vice President, Medical Affairs
  Video: Novavax: NAIIS-Developing COVID-19 Vaccines in Record Time

• Sanofi Pasteur (slides)
  Roman Chicz, PhD
  Global Project Head, Recombinant COVID Vaccine
  Video: Sanofi: BIO Panel: COVID-19 Vaccine Development Update
  

• Dynavax (slides)
  Rob Janssen
  Chief Medical Officer
  Video: Dynavax: CpG 1018 in COVID-19 Vaccines